- Home
- MRNA vs LHX Comparison
MRNA vs LHX Comparison
Compare MRNA & LHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | LHX |
|---|---|---|
| Founded | 2010 | 1895 |
| Country | United States | United States |
| Employees | N/A | 45000 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6B | 54.0B |
| IPO Year | 2018 | 2002 |
Fundamental Metrics
Financial Performance| Metric | MRNA | LHX |
|---|---|---|
| Price | $182.10 | $239.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 10 |
| Target Price | $34.27 | ★ $353.80 |
| AVG Volume (30 Days) | ★ 16.6M | 1.5M |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.56% |
| EPS Growth | ★ 21.77 | 8.39 |
| EPS | N/A | ★ 5.85 |
| Revenue | ★ $19,263,000,000.00 | $6,182,000,000.00 |
| Revenue This Year | $9.36 | $8.25 |
| Revenue Next Year | $15.43 | $7.58 |
| P/E Ratio | ★ N/A | $42.21 |
| Revenue Growth | 4.29 | ★ 4.78 |
| 52 Week Low | $22.28 | $244.76 |
| 52 Week High | $176.86 | $379.23 |
Technical Indicators
Market Signals| Indicator | MRNA | LHX |
|---|---|---|
| Relative Strength Index (RSI) | 68.50 | 30.08 |
| Support Level | $46.85 | $244.76 |
| Resistance Level | $176.66 | $269.50 |
| Average True Range (ATR) | 9.39 | 4.93 |
| MACD | 0.06 | 0.33 |
| Stochastic Oscillator | 87.11 | 10.72 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About LHX L3Harris Technologies Inc.
In addition to its legacy software-defined radio franchise, L3Harris Technologies has, through a series of acquisitions, established franchises producing uncrewed aerial vehicles, sensors, avionics, space-based systems, missiles, and solid rocket motors. It is also adept at refitting civilian aircraft for military use, provides military and commercial training services, and maintains the US Federal Aviation Administration's communication infrastructure.